Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is the IGF-1 Receptor? IGF1R Signaling Explained

Conceptual IGF1R illustration showing two extracellular α subunits linked to two membrane-spanning β subunits with intracellular kinase domains.

The IGF-1 receptor (IGF1R) is a cell-surface receptor tyrosine kinase built from two extracellular α subunits and two membrane-spanning β subunits, an α2β2 heterotetramer. IGF-I and IGF-II both activate it. Ligand binding induces tyrosine autophosphorylation of the β subunits, initiating intracellular signals that can promote cell survival and proliferation.[1]

What IGF1R Is Made Of: Subunits and Domains

Schematic of linked IGF1R halves with extracellular repeat domains and αCT segments, membrane-spanning β regions and intracellular kinase domains.

The α and β subunits are produced by processing a common precursor: it is glycosylated, cleaved by proteases and linked through disulfide bonds to assemble the mature receptor, which has a mass of about 320 kDa. The α subunits remain extracellular, while each β subunit spans the membrane and provides the intracellular signaling machinery. IGF1R shares roughly 60% homology with the insulin receptor and has an ATP-binding site; ATP supplies the phosphate groups for autophosphorylation.[1]

The extracellular region contains leucine-rich repeat domains L1 and L2, a cysteine-rich domain (CR), and three fibronectin type III domains (F1–F3). The tyrosine kinase domain lies inside the cell. The C-terminal region of the α subunit, αCT, forms an α-helix that associates with L1; together they form the site-1 ligand-binding surface. In human IGF1R, αCT spans residues 682–704. A cysteine triplet at Cys669, Cys670 and Cys672, just before the αCT helix, forms disulfide bonds linking the two protomers. This covalent connection physically couples the two αCT regions and constrains their movement during activation.[2]

How IGF-I Binding Activates the IGF1R Kinase

Activation involves rearranging an already linked receptor, rather than simply bringing two separate receptors together. Cryo-EM work on full-length mouse IGF1R resolved a Γ-shaped asymmetric dimer carrying a single IGF-I. When the αCT regions were engineered for greater flexibility, the receptor could form a T-shaped symmetric dimer with two IGF-I molecules bound. In the wild-type structure, the coupled αCTs restrict movement of the unoccupied partner’s L1/αCT region, making binding of a second IGF-I less favorable. This is negative cooperativity: occupancy of one binding site reduces the ease of ligand binding at the other.[2]

Ligand-bound IGF1R can adopt multiple conformations. A structural study reported ten IGF1R structures bound to IGF-I or insulin, with αCT2, the C670–C670′ disulfide and FnIII-2 showing particularly variable orientations. Its abstract also describes a tentatively named diverter-switch state. These are structural classifications, not measurements of downstream signaling activity.[3]

Ligand recognition on the outside is coupled to kinase activation on the inside. In 293FT cell experiments, IGF-I-induced receptor autophosphorylation was monitored at tyrosines 1135 and 1136. Wild-type receptor phosphorylation peaked at 60 minutes and remained at least 80% of that peak after three hours under those experimental conditions. ERK1/2 phosphorylation was measured alongside receptor phosphorylation as a downstream readout. These measurements distinguish activation of the receptor itself from propagation of its signal.[2]

The Two Main IGF1R Signaling Arms

Activated IGF1R phosphorylates insulin receptor substrate (IRS) proteins and Shc. Their phosphotyrosines provide recognition sites for proteins containing Src homology 2 (SH2) domains, including the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), growth factor receptor-bound protein 2 (GRB2), and SHP2. These interactions connect receptor activation to PI3K and Ras–MAPK signaling.[4] PI3K phosphorylates PIP2 to produce PIP3, which then recruits AKT to the plasma membrane, where AKT is phosphorylated and activated.[5]

IRS-1 participates in this network, but it is not universally the preferred IRS substrate. In primary human skeletal muscle myoblasts, receptor-blocking experiments showed an IGF1R contribution to IRS-1 phosphorylation in response to insulin or an insulin analog with enhanced IGF1R affinity. In that experimental setting, IRS-2 rather than IRS-1 was the preferred IGF1R substrate.[6]

IRS-1 and IRS-2 also produced distinct phosphorylation patterns in mouse brown preadipocytes. Comparing wild-type cells with cells lacking either substrate revealed preferential kinase-associated patterns: PDHK1, MAPK3 and PKD1 were associated with IRS-1, while PIN1 and PKCβ were associated with IRS-2. This mouse-cell phosphoproteomic study supports different roles for the two substrates rather than treating them as interchangeable links.[7]

The two main signaling arms are commonly summarized as PI3K–Akt and Shc–Ras–MAPK.[8] IRS proteins and Shc connect the receptor to a network, not two isolated switches. Activation of the PI3K and Ras–MAPK pathways contributes to IGF-induced proliferation, differentiation and survival; these outcomes are not assigned exclusively to one branch in the signaling review abstract.[4]

Endocytosis, Recycling, and Signal Shutdown

Conceptual IGF1R trafficking illustration showing uptake into an early endosome, recycling to the surface and a separate degradation route.

Internalization does not necessarily switch IGF1R signaling off immediately. Activated IGF1R can enter the cell through clathrin-mediated endocytosis. In the cell experiments accompanying the structural work, most wild-type receptor signal was intracellular after one hour of IGF-I stimulation. The kinase inhibitor BMS536924 prevented this internalization, supporting a requirement for kinase activation in that system.[2]

Cancer-cell and tumor-model literature describes two uptake routes: AP2A1/2-associated clathrin-dependent endocytosis and flotillin-1-associated noncaveolar lipid raft uptake. The former has been reported to dominate at higher IGF-I concentrations, while the latter is more sensitive at lower concentrations. Internalized IGF1R can enter Rab5-positive early endosomes and form active complexes with signaling proteins such as IRS and Akt, allowing signaling to continue away from the cell surface.[8]

After uptake, dephosphorylation, ubiquitination-associated degradation and recycling provide different routes for regulating the receptor. Recycling returns receptor to the plasma membrane, whereas degradation removes it from the available pool and contributes to downregulation. Thus, moving receptor off the surface and reducing total receptor availability are distinct events. The same cancer-focused review also describes SUMO1 modification at β-subunit lysines 1025, 1100 and 1120 as necessary for nuclear translocation in the experimental work discussed; mutations at these sites blocked nuclear entry without disrupting classical kinase signaling.[8]

Hybrid Insulin–IGF1 Receptors

IGF1R and the insulin receptor (IR) can form hybrids when their respective pro-receptors heterodimerize. A hybrid combines an IR-derived half with an IGF1R-derived half, rather than consisting entirely of one receptor type. In Chinese hamster ovary (CHO) cells co-expressing receptor constructs, both IR-A–IGF1R and IR-B–IGF1R hybrids bound IGF-I and IGF-II with high affinity comparable to IGF1R homodimers. Their insulin affinity was relatively low and intermediate between that of IR and IGF1R homodimers.[9]

Incorporating a significant fraction of either IR isoform into hybrids abolished insulin-stimulated, but not IGF-I-stimulated, autophosphorylation under the study conditions. The twelve amino acids encoded by IR exon 11 had little or no effect on hybrid ligand binding and activation. These results describe recombinant CHO-cell receptor pharmacology, not the abundance of hybrid receptors in human tissues.[9] Because each hybrid pairs one IR protomer with one IGF1R protomer, a cell can carry IR homodimers, IGF1R homodimers and hybrid receptors at once, and the proportions among the three shift the balance between IGF-I/IGF-II–driven and insulin-driven signaling. IGF-II activates the insulin receptor isoform A as well as IGF1R, so in cells expressing both receptors, IGF-II-driven responses cannot be attributed entirely to IGF1R.[10]

What Human IGF1R Variants Show

Abuzzahab and colleagues identified IGF1R variants in two children from separate groups investigated for growth impairment: a girl with compound heterozygous exon 2 variants Arg108Gln and Lys115Asn, and a boy with the nonsense variant Arg59stop. Cultured fibroblasts from the girl had reduced IGF-I receptor function, while the boy’s fibroblasts had fewer IGF-I receptors. Both children had intrauterine growth retardation and poor postnatal growth. These rare-variant human observations connect receptor function or number with growth, but they are not intervention results.[11]

The mouse Igf1r-null phenotype provides a separate developmental comparison. Mice homozygous for a targeted Igf1r disruption die at birth from respiratory failure and reach about 45% of normal size, with generalized organ hypoplasia, including muscle, and delayed ossification.[12] A complete Igf1r null in laboratory mice is not the same observation as the reduced receptor function or number seen in these two children, and the mouse lethal phenotype should not be read as the expected outcome for children carrying such variants.

Related research: What Is IGF-1 LR3; How Do IGF-Binding Proteins Affect IGF-1 LR3?; IGF-1 LR3.

Research Use Only. This article is for laboratory research and analytical education only. It is not a validated experimental protocol or medical or veterinary advice. The materials discussed are not for administration to humans or animals.

References

  1. Insulin-like growth factor 1 receptor — Wikipedia
  2. Molecular basis for the role of disulfide-linked αCTs in the activation of insulin-like growth factor 1 receptor and insulin receptor (eLife, 2022)
  3. Cryo-EM Structure Reveals Polymorphic Ligand-bound States of IGF1R (J Mol Biol, 2022; abstract)
  4. IGF1 receptor signaling pathways (Hakuno & Takahashi, J Mol Endocrinol, 2018; abstract)
  5. The signaling landscape of insulin-like growth factor 1 (Khan, Zugaza & Torres Aleman, J Biol Chem, 2024)
  6. Differential phosphorylation of IRS-1 and IRS-2 by insulin and IGF-I receptors (2006; abstract)
  7. Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action (Cell Signal, 2018; abstract)
  8. Beyond the membrane: Internalization and compartmentalization of insulin-like growth factor 1 receptor signaling in cancer (Int J Oncol, 2026)
  9. Characterization of insulin/IGF hybrid receptors (Slaaby et al., Biochem J, 2007; abstract)
  10. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity (2011; abstract)
  11. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation (Abuzzahab et al., N Engl J Med, 2003; abstract)
  12. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) (Liu et al., Cell 1993)